|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection |
| Phillip Koo, MD |
| Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate. |
|
|
|
|
|
|
|
|
|
|
|
| Non-Invasive Detection of Neuroendocrine Prostate Cancer Through Targeted Cell-Free DNA Methylation |
Himisha Beltran, MD, and Francesca Demichelis, MSc, PhD
Andrea Miyahira discusses a study on noninvasive detection of neuroendocrine prostate cancer with Himisha Beltran and Francesca Demichelis. Their collaborative paper, published in Cancer Discovery, introduces a targeted cell-free DNA methylation panel called NEMO (Neuroendocrine Monitoring). |
|
|
|
|
|
|
|
|
|
|
|
A Urine-Based Multiplexed Assay for the Early Detection of Aggressive Prostate Cancer
|
|
Simpa Salami, MD, MPH
|
| In this conversation with Charles Ryan, Simpa Salami highlights a new urine-based test for detecting aggressive prostate cancer, which promises improvement upon current biomarker tests. It's been estimated that prostate cancer often occurs in multiple areas of the prostate in about 60% to 80% of patients.
|
|
|
|
|
|
|
|
|
|
|
|
Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U - Beyond the Abstract
|
| Hendrik Van Poppel, MD & Vera Vasilyeva, MD |
| The PRAISE-U project aims to enhance early detection of prostate cancer in Europe through risk-based screening, moving away from the traditional one-size-fits-all approach. By collaborating with multidisciplinary partners, PRAISE-U is developing a flexible algorithm for individualized risk stratification, with initial findings on the outcomes and cost-effectiveness of current screening practices expected by the end of 2023. |
|
|
|
|
|
Prospective Validation Study of a Novel Integrated Pathway Based on Clinical Features, Magnetic Resonance Imaging Biomarkers, and MicroRNAs for Early Detection of Prostate Cancer - Beyond the Abstract
|
| Martina Pecoraro, Giuseppina Catanzaro, Federica Conte et al. |
| The STITCH center at Sapienza University initiated an interdisciplinary project to enhance prostate cancer diagnostics through network medicine, combining clinical features, MRI biomarkers, and microRNAs. Their prospective validation study identified miR-302a-5p and miR-367-3p as key biomarkers, integrated into a diagnostic pathway that accurately allocated patients for biopsy, reducing overdiagnosis and overtreatment. |
|
|
|
|
|
|
|
|
|
|
Transperineal or Transrectal Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer Detection - Beyond the Abstract
|
| Romain Diamand, MD, PhD, MCU, FEBU |
| A study analyzing data from 4,841 European patients compared the effectiveness of transrectal versus transperineal MRI-targeted biopsies for detecting clinically significant prostate cancer. Findings revealed that transperineal biopsies had higher rates of csPCa detection and are associated with fewer severe urinary tract infections, aligning with the European Association of Urology's preference for transperineal biopsies. |
|
|
|
|
|
| Should I Order a PET Scan? Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities |
| Marc Bjurlin, DO, MSc, FACOS |
| Marc Bjurlin discusses the integration of molecular imaging into urologic oncology practice. Highlighting various radiopharmaceuticals and imaging techniques, he emphasized the significant impact of PSMA PET in prostate cancer management and the promising potential of molecular imaging in differentiating renal tumor histologies. |
|
|
|
|
|
| COBRA: Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy |
| Luke Nordquist, MD, FACP |
| Luke Nordquist presented results from the COBRA study, which assessed the safety and efficacy of 64Cu-SAR-bisPSMA in detecting prostate cancer lesions in patients with biochemical recurrence. The study found that 64Cu-SAR-bisPSMA, with its longer half-life and higher tumor uptake compared to other PSMA agents, detected more lesions (up to 80% of patients) and smaller lesions (as small as 2 mm) on next-day imaging. |
|
|
|
|
|
|
|
|
|
|
